How to efficiently move towards primary prevention in sporadic AD
Reisa Anne Sperling, REMA RAMAN. Alzheimer s & Dementia, 2025-12-01
Topic: Risk, prevention and care in population studies
The findings from the AHEAD Study screening process and longitudinal data from the LEARN Study are providing critical data to guide future prevention trial design. The Alzheimer Plasma Extension Study (APEX) is enrolling over 1000 individuals who did not meet amyloid eligibility criteria for AHEAD but showed subtle biomarker abnormalities on plasma testing. APEX is oversampling individuals from underserved racial and ethnic communities to evaluate longitudinal trajectories in AD biomarkers, but also markers of vascular, metabolic and inflammatory processes that may contribute to cognitive decline in diverse communities. Optimizing clinical trial design is essential for advancing Alzheimer's prevention on a global scale. Building large international cohorts with "run-in" plasma biomarker data with global collaborations will serve to accelerate the development and accessibility of Alzheimer's prevention solutions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sperling, R. A., & RAMAN, R. E. M. A. (2025). How to efficiently move towards primary prevention in sporadic AD. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_105951
Vancouver
Sperling RA, RAMAN REMA. How to efficiently move towards primary prevention in sporadic AD. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_105951. PMID: 41450236.
BibTeX
@article{sperling2025-41450236,
author = {Sperling, Reisa Anne and RAMAN, REMA},
title = {{How to efficiently move towards primary prevention in sporadic AD}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70859_105951},
pmid = {41450236},
url = {https://doi.org/10.1002/alz70859_105951}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The findings from the AHEAD Study screening process and longitudinal data from the LEARN Study are providing critical data to guide future prevention trial design.
- The Alzheimer Plasma Extension Study (APEX) is enrolling over 1000 individuals who did not meet amyloid eligibility criteria for AHEAD but showed subtle biomarker abnormalities on plasma testing.
- APEX is oversampling individuals from underserved racial and ethnic communities to evaluate longitudinal trajectories in AD biomarkers, but also markers of vascular, metabolic and inflammatory processes that may contribute to cognitive decline in diverse communities.
- Optimizing clinical trial design is essential for advancing Alzheimer's prevention on a global scale.
- Building large international cohorts with "run-in" plasma biomarker data with global collaborations will serve to accelerate the development and accessibility of Alzheimer's prevention solutions.
Why it matters
This paper discusses how data from prevention trials and cohort studies are being used to improve the design of future Alzheimer's prevention trials. It describes ongoing efforts to build large international cohorts and include underserved communities, but does not report results of a treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designlongitudinal study
- Participants1,000
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author REMA RAMAN: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Brigham and Women's Hospital: institution h-index 1,995 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41450236) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70859_105951
- PubMed: 41450236
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Genetics
Also in Genetics
173 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.